(Q38193589)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

review article

1 reference

title

Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

I Poschke

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

R Kiessling

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

24 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

276

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

154-170

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24597954%20AND%20SRC:MED&resulttype=core&format=json

Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Macrophage regulation of tumor responses to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Paradoxical roles of the immune system during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

On the armament and appearances of human myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

A cross-sectional analysis of physical activity and obesity indicators in European participants of the EPIC-PANACEA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Beyond oxidative stress: an immunologist's guide to reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

The many roles of NOX2 NADPH oxidase-derived ROS in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Superoxide and hydrogen peroxide in relation to mammalian cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Reactive oxygen species: a breath of life or death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Central memory and effector memory T cell subsets: function, generation, and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Arginase: an emerging key player in the mammalian immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

L-arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Elevated serum arginase activity levels in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Arginine metabolism: nitric oxide and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

L-arginine availability regulates T-lymphocyte cell-cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

TGF-beta and kynurenines as the key to infectious tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Nitric oxide: a cytotoxic activated macrophage effector molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Role of nitric oxide in carcinogenesis and tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation - a novel antiapoptotic mechanism that suppresses apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Uveal melanoma: the inflammatory microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Nitric oxide and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Proinflammatory S100 proteins in arthritis and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

S100A9 a new marker for monocytic human myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

21 January 2018

S100A9 and tumor growth

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Emerging molecularly targeted therapies in castration refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Prostaglandins as modulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Cox-2 expression in ovarian malignancies: a review of the clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Role of prostaglandin E2 in peptidoglycan mediated iNOS expression in mouse peritoneal macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Prostaglandin E2 augments IL-10 signaling and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Coxibs and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

GM-CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Mammary tumor suppression by transforming growth factor beta 1 transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Reducing mammary cancer risk through premature stem cell senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Bidirectional regulation of macrophage function by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229

Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12229